Changes
On February 7, 2023 at 8:10:41 AM UTC, Chimwemwe Mkandawire:
-
No fields were updated. See the metadata diff for more details.
f | 1 | { | f | 1 | { |
2 | "author": "", | 2 | "author": "", | ||
3 | "author_email": "", | 3 | "author_email": "", | ||
4 | "creator_user_id": "c64e3919-2d1c-42bf-835b-e85a6be9792c", | 4 | "creator_user_id": "c64e3919-2d1c-42bf-835b-e85a6be9792c", | ||
5 | "groups": [], | 5 | "groups": [], | ||
6 | "id": "902c158b-ed44-419f-b3e8-1ad27ef23087", | 6 | "id": "902c158b-ed44-419f-b3e8-1ad27ef23087", | ||
7 | "isopen": false, | 7 | "isopen": false, | ||
8 | "license_id": "notspecified", | 8 | "license_id": "notspecified", | ||
9 | "license_title": "License not specified", | 9 | "license_title": "License not specified", | ||
10 | "maintainer": null, | 10 | "maintainer": null, | ||
11 | "maintainer_email": null, | 11 | "maintainer_email": null, | ||
12 | "metadata_created": "2023-02-07T08:10:01.302272", | 12 | "metadata_created": "2023-02-07T08:10:01.302272", | ||
n | 13 | "metadata_modified": "2023-02-07T08:10:41.121058", | n | 13 | "metadata_modified": "2023-02-07T08:10:41.502243", |
14 | "name": "malawi-integrated-hiv-program-report-2021-q4", | 14 | "name": "malawi-integrated-hiv-program-report-2021-q4", | ||
15 | "notes": "__Program performance highlights by the end of September | 15 | "notes": "__Program performance highlights by the end of September | ||
16 | 2021 include:__\r\n\r\n* Scale-up of integrated HIV services had | 16 | 2021 include:__\r\n\r\n* Scale-up of integrated HIV services had | ||
17 | reached the following number of sites:\r\n * 727 static and 158 | 17 | reached the following number of sites:\r\n * 727 static and 158 | ||
18 | outreach HIV testing sites.\r\n * 783 (static) ART sites; 623 of | 18 | outreach HIV testing sites.\r\n * 783 (static) ART sites; 623 of | ||
19 | these started at least one pregnant or breastfeeding woman.\r\n | 19 | these started at least one pregnant or breastfeeding woman.\r\n | ||
20 | * 701 sites with HIV-exposed children in follow-up.\r\n* __684,267__ | 20 | * 701 sites with HIV-exposed children in follow-up.\r\n* __684,267__ | ||
21 | persons were tested for HIV by a trained provider and received their | 21 | persons were tested for HIV by a trained provider and received their | ||
22 | results; __125,567 (18%)__ accessed HIV testing for the first time; | 22 | results; __125,567 (18%)__ accessed HIV testing for the first time; | ||
23 | __535,955 (82%)__ were repeat testers and __22,260 (4%)__ of these | 23 | __535,955 (82%)__ were repeat testers and __22,260 (4%)__ of these | ||
24 | received confirmatory testing (after having tested positive in the | 24 | received confirmatory testing (after having tested positive in the | ||
25 | past). __19,453 (3.0%)__ clients received a positive result for the | 25 | past). __19,453 (3.0%)__ clients received a positive result for the | ||
26 | first time.\r\n* A total of __130,070__ people received __211,801__ | 26 | first time.\r\n* A total of __130,070__ people received __211,801__ | ||
27 | self-test kits; __107,165 (51%)__ of these were for use by the | 27 | self-test kits; __107,165 (51%)__ of these were for use by the | ||
28 | recipient and __104,633 (49%)__ for onward distribution to sex | 28 | recipient and __104,633 (49%)__ for onward distribution to sex | ||
29 | partners or other people.\r\n* __18,888 (97%)__ of __19,548__ blood | 29 | partners or other people.\r\n* __18,888 (97%)__ of __19,548__ blood | ||
30 | units collected were screened for (at least) HIV, hepatitis B and | 30 | units collected were screened for (at least) HIV, hepatitis B and | ||
31 | syphilis.\r\n* A cumulative total of 13,835 clients were referred for | 31 | syphilis.\r\n* A cumulative total of 13,835 clients were referred for | ||
32 | PrEP eligibility screening and __12,890 (93%)__ were found eligible. | 32 | PrEP eligibility screening and __12,890 (93%)__ were found eligible. | ||
33 | __11,221 (87%)__ were enrolled in PrEP and __7,631 (68%)__ clients | 33 | __11,221 (87%)__ were enrolled in PrEP and __7,631 (68%)__ clients | ||
34 | were retained on PrEP at the end of the December 2021.\r\n* __157,139 | 34 | were retained on PrEP at the end of the December 2021.\r\n* __157,139 | ||
35 | (95%)__ of __164,803__ women at ANC had their HIV status ascertained; | 35 | (95%)__ of __164,803__ women at ANC had their HIV status ascertained; | ||
36 | __8,367 (5%)__ of these were HIV positive. __135,464 (98%)__ of | 36 | __8,367 (5%)__ of these were HIV positive. __135,464 (98%)__ of | ||
37 | __144,231__ at maternity had their HIV status ascertained __8,290 | 37 | __144,231__ at maternity had their HIV status ascertained __8,290 | ||
38 | (6%)__ of these were HIV positive.\r\n* __19,463__ patients started | 38 | (6%)__ of these were HIV positive.\r\n* __19,463__ patients started | ||
39 | ART this quarter; __88%__ were classified as asymptomatic / in WHO | 39 | ART this quarter; __88%__ were classified as asymptomatic / in WHO | ||
40 | stage 1 and started under the \u201cTest & Treat\u201d policy.\r\n* | 40 | stage 1 and started under the \u201cTest & Treat\u201d policy.\r\n* | ||
41 | __898,132__ patients were alive and on ART by end of December 2021.2 | 41 | __898,132__ patients were alive and on ART by end of December 2021.2 | ||
42 | This means that 91% of the estimated __986,240__ HIV positive | 42 | This means that 91% of the estimated __986,240__ HIV positive | ||
43 | population was on ART. ART coverage was __78% (42,771/ 54,742)__ for | 43 | population was on ART. ART coverage was __78% (42,771/ 54,742)__ for | ||
44 | children and __92% (855,361 / 931,449)__ for adults.\r\n* __87,938 | 44 | children and __92% (855,361 / 931,449)__ for adults.\r\n* __87,938 | ||
45 | (93%)__ of viral load results from routine monitoring were <1000 | 45 | (93%)__ of viral load results from routine monitoring were <1000 | ||
46 | copies/ml. Viral suppression rates for routine samples among children | 46 | copies/ml. Viral suppression rates for routine samples among children | ||
47 | (0-14 years) and adults (15+ years) were 76% and 94%, | 47 | (0-14 years) and adults (15+ years) were 76% and 94%, | ||
48 | respectively.\r\n* __80%__ of adults and __81%__ of children were | 48 | respectively.\r\n* __80%__ of adults and __81%__ of children were | ||
49 | retained alive on ART at 12 months after initiation.\r\n* Out of | 49 | retained alive on ART at 12 months after initiation.\r\n* Out of | ||
50 | __893,136__ patients on first line adult ART 853,785 (97%) had | 50 | __893,136__ patients on first line adult ART 853,785 (97%) had | ||
51 | transitioned to TDF/3TC/DTG and only __1,571 (<1%)__ were on | 51 | transitioned to TDF/3TC/DTG and only __1,571 (<1%)__ were on | ||
52 | TDF/3TC/EFV.\r\n* __9,001 6 (92%)__ of an estimated __9,798__ HIV | 52 | TDF/3TC/EFV.\r\n* __9,001 6 (92%)__ of an estimated __9,798__ HIV | ||
53 | infected pregnant women in Malawi were on ART this quarter. __6,314 | 53 | infected pregnant women in Malawi were on ART this quarter. __6,314 | ||
54 | (70%)__ of these were already on ART when getting pregnant and __2,687 | 54 | (70%)__ of these were already on ART when getting pregnant and __2,687 | ||
55 | (30%)__ started ART during pregnancy/delivery.\r\n* An additional | 55 | (30%)__ started ART during pregnancy/delivery.\r\n* An additional | ||
56 | __883__ breastfeeding women (re-)started ART in WHO stage 1 or 2.\r\n* | 56 | __883__ breastfeeding women (re-)started ART in WHO stage 1 or 2.\r\n* | ||
57 | __86%__ and __82%__ of women started while pregnant or breastfeeding | 57 | __86%__ and __82%__ of women started while pregnant or breastfeeding | ||
58 | were retained on ART at 6 and 12 months after initiation, | 58 | were retained on ART at 6 and 12 months after initiation, | ||
59 | respectively.\r\n* __7,747 (7%)__ of infants discharged alive from | 59 | respectively.\r\n* __7,747 (7%)__ of infants discharged alive from | ||
60 | maternity were known to be HIV exposed, __7,465 (96%)__ of these | 60 | maternity were known to be HIV exposed, __7,465 (96%)__ of these | ||
61 | received ARV prophylaxis (nevirapine).\r\n* A total of __11,247__ HIV | 61 | received ARV prophylaxis (nevirapine).\r\n* A total of __11,247__ HIV | ||
62 | exposed children were newly enrolled for follow-up this quarter; | 62 | exposed children were newly enrolled for follow-up this quarter; | ||
63 | __11,186 (80%)__ of these were enrolled before age 2 months.\r\n* Out | 63 | __11,186 (80%)__ of these were enrolled before age 2 months.\r\n* Out | ||
64 | of the total __986,240__ estimated PLHIV by end December 2021:", | 64 | of the total __986,240__ estimated PLHIV by end December 2021:", | ||
65 | "num_resources": 1, | 65 | "num_resources": 1, | ||
66 | "num_tags": 9, | 66 | "num_tags": 9, | ||
67 | "organization": { | 67 | "organization": { | ||
68 | "approval_status": "approved", | 68 | "approval_status": "approved", | ||
69 | "created": "2021-10-14T11:02:35.234558", | 69 | "created": "2021-10-14T11:02:35.234558", | ||
70 | "description": "The Department of HIV & AIDS (DHA) was established | 70 | "description": "The Department of HIV & AIDS (DHA) was established | ||
71 | in 2001, initially as a unit in the Department of Clinical Services, | 71 | in 2001, initially as a unit in the Department of Clinical Services, | ||
72 | to coordinate the biomedical HIV Program in Malawi. The department now | 72 | to coordinate the biomedical HIV Program in Malawi. The department now | ||
73 | carries responsibility for various HIV related programs including: | 73 | carries responsibility for various HIV related programs including: | ||
74 | sexually transmitted infections (STIs), prevention of mother to child | 74 | sexually transmitted infections (STIs), prevention of mother to child | ||
75 | transmission of HIV (PMTCT), and national voluntary male medical | 75 | transmission of HIV (PMTCT), and national voluntary male medical | ||
76 | circumcision program (VMMC). All these HIV program sub-sections are | 76 | circumcision program (VMMC). All these HIV program sub-sections are | ||
77 | linked to one robust monitoring and evaluation sub-section in the HIV | 77 | linked to one robust monitoring and evaluation sub-section in the HIV | ||
78 | and AIDS Department which technically operates under the Central | 78 | and AIDS Department which technically operates under the Central | ||
79 | Monitoring and Evaluation Department (CMED) of the Ministry of | 79 | Monitoring and Evaluation Department (CMED) of the Ministry of | ||
80 | Health.", | 80 | Health.", | ||
81 | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | 81 | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | ||
82 | "image_url": | 82 | "image_url": | ||
83 | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | 83 | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | ||
84 | "is_organization": true, | 84 | "is_organization": true, | ||
85 | "name": "dha", | 85 | "name": "dha", | ||
86 | "state": "active", | 86 | "state": "active", | ||
87 | "title": "Department of HIV & AIDS and Viral Hepatitis", | 87 | "title": "Department of HIV & AIDS and Viral Hepatitis", | ||
88 | "type": "organization" | 88 | "type": "organization" | ||
89 | }, | 89 | }, | ||
90 | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | 90 | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | ||
91 | "private": false, | 91 | "private": false, | ||
92 | "program_area": "Care and Treatment", | 92 | "program_area": "Care and Treatment", | ||
93 | "relationships_as_object": [], | 93 | "relationships_as_object": [], | ||
94 | "relationships_as_subject": [], | 94 | "relationships_as_subject": [], | ||
95 | "resources": [ | 95 | "resources": [ | ||
96 | { | 96 | { | ||
97 | "cache_last_updated": null, | 97 | "cache_last_updated": null, | ||
98 | "cache_url": null, | 98 | "cache_url": null, | ||
99 | "created": "2023-02-07T08:10:41.148982", | 99 | "created": "2023-02-07T08:10:41.148982", | ||
100 | "description": "", | 100 | "description": "", | ||
101 | "format": "PDF", | 101 | "format": "PDF", | ||
102 | "hash": "", | 102 | "hash": "", | ||
103 | "id": "e2424210-403b-47f3-868c-8435ee14c1c4", | 103 | "id": "e2424210-403b-47f3-868c-8435ee14c1c4", | ||
104 | "last_modified": "2023-02-07T08:10:41.112505", | 104 | "last_modified": "2023-02-07T08:10:41.112505", | ||
105 | "lfs_prefix": | 105 | "lfs_prefix": | ||
106 | "dha/malawi-integrated-hiv-program-report-2021-q4", | 106 | "dha/malawi-integrated-hiv-program-report-2021-q4", | ||
n | 107 | "metadata_modified": "2023-02-07T08:10:41.126034", | n | 107 | "metadata_modified": "2023-02-07T08:10:41.506917", |
108 | "mimetype": "application/pdf", | 108 | "mimetype": "application/pdf", | ||
109 | "mimetype_inner": null, | 109 | "mimetype_inner": null, | ||
110 | "name": "Malawi Integrated HIV Program Report 2021 Q4", | 110 | "name": "Malawi Integrated HIV Program Report 2021 Q4", | ||
111 | "package_id": "902c158b-ed44-419f-b3e8-1ad27ef23087", | 111 | "package_id": "902c158b-ed44-419f-b3e8-1ad27ef23087", | ||
112 | "position": 0, | 112 | "position": 0, | ||
113 | "resource_type": null, | 113 | "resource_type": null, | ||
114 | "sha256": | 114 | "sha256": | ||
115 | "1585a52e1e46cb4ed9403ef7b7c4d68c103e1adda6cb1cd6604ec59e566639a7", | 115 | "1585a52e1e46cb4ed9403ef7b7c4d68c103e1adda6cb1cd6604ec59e566639a7", | ||
116 | "size": 4339613, | 116 | "size": 4339613, | ||
117 | "state": "active", | 117 | "state": "active", | ||
118 | "url": | 118 | "url": | ||
119 | 35ee14c1c4/download/malawi_integrated_hiv_program_report_2021_q4.pdf", | 119 | 35ee14c1c4/download/malawi_integrated_hiv_program_report_2021_q4.pdf", | ||
120 | "url_type": "upload" | 120 | "url_type": "upload" | ||
121 | } | 121 | } | ||
122 | ], | 122 | ], | ||
t | 123 | "state": "draft", | t | 123 | "state": "active", |
124 | "tags": [ | 124 | "tags": [ | ||
125 | { | 125 | { | ||
126 | "display_name": "HTC", | 126 | "display_name": "HTC", | ||
127 | "id": "6a53fcf5-e774-4295-b9c3-32da8b896f9b", | 127 | "id": "6a53fcf5-e774-4295-b9c3-32da8b896f9b", | ||
128 | "name": "HTC", | 128 | "name": "HTC", | ||
129 | "state": "active", | 129 | "state": "active", | ||
130 | "vocabulary_id": null | 130 | "vocabulary_id": null | ||
131 | }, | 131 | }, | ||
132 | { | 132 | { | ||
133 | "display_name": "PMTCT-ART", | 133 | "display_name": "PMTCT-ART", | ||
134 | "id": "83bf82ef-383c-46e2-a80c-f3431b3f99e2", | 134 | "id": "83bf82ef-383c-46e2-a80c-f3431b3f99e2", | ||
135 | "name": "PMTCT-ART", | 135 | "name": "PMTCT-ART", | ||
136 | "state": "active", | 136 | "state": "active", | ||
137 | "vocabulary_id": null | 137 | "vocabulary_id": null | ||
138 | }, | 138 | }, | ||
139 | { | 139 | { | ||
140 | "display_name": "anc", | 140 | "display_name": "anc", | ||
141 | "id": "1e47aae6-8e3d-41e7-9b1a-778af0d2f23a", | 141 | "id": "1e47aae6-8e3d-41e7-9b1a-778af0d2f23a", | ||
142 | "name": "anc", | 142 | "name": "anc", | ||
143 | "state": "active", | 143 | "state": "active", | ||
144 | "vocabulary_id": null | 144 | "vocabulary_id": null | ||
145 | }, | 145 | }, | ||
146 | { | 146 | { | ||
147 | "display_name": "blood safety", | 147 | "display_name": "blood safety", | ||
148 | "id": "24fd7907-18be-4ad1-80ad-ba65da6a9707", | 148 | "id": "24fd7907-18be-4ad1-80ad-ba65da6a9707", | ||
149 | "name": "blood safety", | 149 | "name": "blood safety", | ||
150 | "state": "active", | 150 | "state": "active", | ||
151 | "vocabulary_id": null | 151 | "vocabulary_id": null | ||
152 | }, | 152 | }, | ||
153 | { | 153 | { | ||
154 | "display_name": "hiv", | 154 | "display_name": "hiv", | ||
155 | "id": "43013fde-ebf4-470e-9e5d-1a3aa939d404", | 155 | "id": "43013fde-ebf4-470e-9e5d-1a3aa939d404", | ||
156 | "name": "hiv", | 156 | "name": "hiv", | ||
157 | "state": "active", | 157 | "state": "active", | ||
158 | "vocabulary_id": null | 158 | "vocabulary_id": null | ||
159 | }, | 159 | }, | ||
160 | { | 160 | { | ||
161 | "display_name": "marternity", | 161 | "display_name": "marternity", | ||
162 | "id": "6b01b92e-282f-4812-a909-8fb4b479d0d1", | 162 | "id": "6b01b92e-282f-4812-a909-8fb4b479d0d1", | ||
163 | "name": "marternity", | 163 | "name": "marternity", | ||
164 | "state": "active", | 164 | "state": "active", | ||
165 | "vocabulary_id": null | 165 | "vocabulary_id": null | ||
166 | }, | 166 | }, | ||
167 | { | 167 | { | ||
168 | "display_name": "report", | 168 | "display_name": "report", | ||
169 | "id": "80c23033-8ff3-483d-8aa6-03e39b117372", | 169 | "id": "80c23033-8ff3-483d-8aa6-03e39b117372", | ||
170 | "name": "report", | 170 | "name": "report", | ||
171 | "state": "active", | 171 | "state": "active", | ||
172 | "vocabulary_id": null | 172 | "vocabulary_id": null | ||
173 | }, | 173 | }, | ||
174 | { | 174 | { | ||
175 | "display_name": "sti", | 175 | "display_name": "sti", | ||
176 | "id": "38222aa3-73ca-4ca8-8b42-9a5eb558af5a", | 176 | "id": "38222aa3-73ca-4ca8-8b42-9a5eb558af5a", | ||
177 | "name": "sti", | 177 | "name": "sti", | ||
178 | "state": "active", | 178 | "state": "active", | ||
179 | "vocabulary_id": null | 179 | "vocabulary_id": null | ||
180 | }, | 180 | }, | ||
181 | { | 181 | { | ||
182 | "display_name": "viral load", | 182 | "display_name": "viral load", | ||
183 | "id": "e385a0a4-1722-431f-a657-f9616a14bf6f", | 183 | "id": "e385a0a4-1722-431f-a657-f9616a14bf6f", | ||
184 | "name": "viral load", | 184 | "name": "viral load", | ||
185 | "state": "active", | 185 | "state": "active", | ||
186 | "vocabulary_id": null | 186 | "vocabulary_id": null | ||
187 | } | 187 | } | ||
188 | ], | 188 | ], | ||
189 | "title": "Malawi Integrated HIV Program Report 2021 Q4", | 189 | "title": "Malawi Integrated HIV Program Report 2021 Q4", | ||
190 | "type": "dataset", | 190 | "type": "dataset", | ||
191 | "url": null, | 191 | "url": null, | ||
192 | "version": null, | 192 | "version": null, | ||
193 | "year": "2021" | 193 | "year": "2021" | ||
194 | } | 194 | } |